

Pfizer Cyprus - 2020

Date of publication : 31 - 10 - 2023

	Full Name  (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered  (Art. 3)	Country of Principal Practice  (Schedule 1)	Principal Practice Address  (Art. 3)	Unique country Identifier OPTIONAL  (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)  ( EUR )	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL - OPTIONAL  ( EUR )
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event  ( EUR )	Registration Fees  ( EUR )	Travel & Accommodation  ( EUR )	Fees  ( EUR )	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract  ( EUR )	
<b>HCPs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	ZANNETOY XATZHXPITOTHH, NEΔH	ΣΤΡΟΒΟΛΟΣ	CY	ΛΕΩΦ.ΛΕΥΚΟΘΕΟΥ 20		N/A	N/A	175,00	0,00	0,00	0,00	175,00
	ΧΡΥΣΟΣΤΟΜΟΥ, ΣΤΕΛΙΝΑ	ΣΤΡΟΒΟΛΟΣ	CY	ΑΝΑΡΓΕΑ ΣΤΡΟΥΓΓΙΔΟΥ 8		N/A	N/A	175,00	0,00	0,00	0,00	175,00
<b>HCOs</b>												
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	4.300,54	3.376,66	0,00	100,00	7.777,20
	Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A	26	5	0	1	27
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A	89,29%	100,00%	0,00%	100,00%	N/A
<b>HCOs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	ΠΑΙΔΙΑΤΡΟΣ-PEDMED SERVICES LTD	ΕΓΚΩΜΗ ΛΕΥΚΩΣΙΑΣ	CY	ΔΙΟΓΕΝΟΥΣ 1	-	0,00	2.600,00	0,00	0,00	0,00	0,00	2.600,00
	ΕΤΑΙΡΕΙΑ ΔΙΑΒΗΤΟΛΟΓΙΑΣ ΚΥΠΡΟΥ	ΛΕΜΕΣΟΣ	CY	ΠΕΚΙΝΟΥ 3	-	0,00	4.500,00	0,00	0,00	0,00	0,00	4.500,00
	ΙΑΤΡΙΚΟΣ ΣΥΛΛΟΓΟΣ ΛΕΥΚΩΣΙΑΣ	ΛΕΥΚΩΣΙΑ	CY	ΘΑΣΟΥ 14	-	0,00	500,00	0,00	0,00	0,00	0,00	500,00
	ΚΑΡΔΙΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ ΚΥΠΡΟΥ	ΣΤΡΟΒΟΛΟΣ	CY	ΚΥΠΡΑΚΟΥ ΕΡΥΘΡ.ΣΤΑΥΡΟΥ	-	0,00	7.735,00	0,00	0,00	0,00	0,00	7.735,00
	ΚΥΠΡΙΑΚΗ ΑΙΜΑΤΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ	ΣΤΡΟΒΟΛΟΣ	CY	ΠΑΛ.ΔΡΟΜΟΣ ΛΕΥΚΩΣΙΑΣ ΛΕΜΕΣΟΥ 215	-	0,00	3.000,00	0,00	0,00	0,00	0,00	3.000,00
	ΠΑΚΚΥΠΡΙΟΣ ΙΑΤΡΙΚΟΣ ΣΥΛΛΟΓΟΣ	ΛΕΥΚΩΣΙΑ	CY	ΘΑΣΟΥ 14	-	20.000,00	8.000,00	0,00	0,00	0,00	0,00	28.000,00
	ΠΑΙΔΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ ΚΥΠΡΟΥ	ΛΕΥΚΩΣΙΑ	CY	ΘΑΣΟΥ 14	-	0,00	6.300,00	0,00	0,00	0,00	0,00	6.300,00
<b>HCOs</b>												
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					0,00	0,00	0,00	0,00	0,00	0,00	0,00
	Number of Recipients in aggregate disclosure - Art. 3.02					0	0	0	0	0	0	0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					0,00%	0,00%	0,00%	0,00%	0,00%	0,00%	N/A
<b>R&amp;D</b>												
<i>AGGREGATE DISCLOSURE</i>												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										TOTAL - AMOUNT	0,00

The publication of this information is made for transparency purposes only, as further detailed in the Pfizer EEA HCP Privacy Policy at <https://privacycenter.pfizer.com/en> (section "Disclosures of transfer of value"). It does not entail a general authorization to those accessing the website to carry out any further processing of health care professionals' (HCPs) data, such as combining it with the information published on other websites.